SEC Form 4 · accession 0001179110-17-013599
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry O Gosebruch
Officer — Chief Strategy Officer
Period of report
Oct 30, 2017
Accepted (ET)
Oct 31, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.01 par valueF1 | Oct 30, 2017 | S | 2,150 | $89.3823 | D | 81,287 | D | |
| Common stock, $0.01 par valueF2 | Oct 30, 2017 | S | 11,568 | $90.4922 | D | 69,719 | D | |
| Common stock, $0.01 par valueF3 | Oct 30, 2017 | S | 4,482 | $91.2203 | D | 65,237 | D | |
| Common stock, $0.01 par value | Oct 30, 2017 | S | 100 | $92.02 | D | 65,137 | D | |
| Common stock, $0.01 par valueF4 | holding | — | — | — | 1,433 | I | Profit sharing trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.93 to $89.86, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.94 to $90.94, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.95 to $91.84, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4Balance in AbbVie Savings Program as of October 30, 2017.
Remarks
The transactions reported on this Form 4 were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).